FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due to safety concerns.

As a result, the market is dumping Sarepta stock, which is down -42% in trading so far today. Sarepta's current market cap valuation has fallen <$6bn, when at the beginning of this week, it had ...

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

U.S. stocks moved higher on Monday as optimism around earnings overshadowed any investor fears over the latest developments ...

Sarepta stock target cut to $184 by Oppenheimer, ... Oppenheimer’s analysts echoed the sentiment that the market’s reaction to the patient death and the European Medicines Agency’s ...

Sarepta Therapeutics' (SRPT) stock continued to sink Monday, down about 5% in early trade, following a rough end to last week ...

Sarepta Therapeutics' (SRPT) stock continued to sink Tuesday, down more than 4% in pre-market trade, following a rough end to ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on SRPT stock, giving a Buy rating on December 29. Joseph Schwartz ...